Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant
Conditions
Interventions
bempedoic acid
placebo
Locations
67
United States
Gilbert, Arizona, United States
Anaheim, California, United States
Long Beach, California, United States
Sacramento, California, United States
Santa Ana, California, United States
Torrance, California, United States
Start Date
November 16, 2016
Primary Completion Date
March 16, 2018
Completion Date
March 16, 2018
Last Updated
April 3, 2020
NCT07473960
NCT00353782
NCT07489209
NCT07037771
NCT07487363
NCT07058077
Lead Sponsor
Esperion Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions